Greenwich Lifesciences Inc (GLSI)

$10.91 +0.26 (2.44%)
Market Cap 148.70M
Revenue (ttm) 0.00
Net Income (ttm) -15.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 46,800
Avg Vol 60,852
Day's Range N/A - N/A
Shares Out 13.63M
Stochastic %K 52%
Beta 1.62
Analysts Strong Sell
Price Target $42.00

Company Profile

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in...

Industry: Biotechnology
Sector: Healthcare
Phone: 832-819-3232
Address:
Building 14, 3992 Bluebonnet Dr., Stafford, United States
Rolltide2020
Rolltide2020 Oct. 4 at 12:38 PM
$GLSI For what it’s worth:
0 · Reply
Alwaysdiversify
Alwaysdiversify Oct. 3 at 2:14 PM
$GLSI Of the 4 basic operations of arithmetic, the one I relish the most is multiplication. For example: My 20,275 shares of GLSI x $100 (my admittedly conservative estimate of a buyout price) = $2,027,500. And, 100% of that will be taxed as long-term capital gains.
4 · Reply
Gulfoil
Gulfoil Oct. 3 at 1:22 PM
$GLSI i dont know but hopefully no one fell victim to the head fake to go back below $10……this is going up. Where it deserves to trade.
2 · Reply
Rolltide2020
Rolltide2020 Oct. 3 at 9:07 AM
$GLSI So which European country are we adding today?
1 · Reply
doc123266
doc123266 Oct. 2 at 10:19 PM
$GLSI green day always nice.
0 · Reply
Edgehockey
Edgehockey Oct. 2 at 6:17 PM
$GLSI The only stock whose shorts are in a more precarious situation is VKTX. Hope you rats are short that name too. My QURE burnt many of you.
0 · Reply
Edgehockey
Edgehockey Oct. 2 at 6:15 PM
$GLSI Shorts- you are in for a world full of hurt. No sellers. You better smash the stock down and spend some more bullets. Spread some rumors on Seeking Alpha and shake out the fearful longs. If GLSI-100 has any performance close to P2, you will be covering at $100/ share.
1 · Reply
Rolltide2020
Rolltide2020 Oct. 2 at 5:29 PM
$GLSI With all this good news lately, we are due to go on a heater soon.
0 · Reply
Edgehockey
Edgehockey Oct. 2 at 2:49 PM
$GLSI Binary: longs downside is $8 bucks.....shorts, $80 bucks. LMFAO.
0 · Reply
Gulfoil
Gulfoil Oct. 2 at 12:09 PM
$GLSI pretty annoying you have to call in to buy
1 · Reply
Latest News on GLSI
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Oct 2, 2025, 6:00 AM EDT - 2 days ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Sep 30, 2025, 6:00 AM EDT - 4 days ago

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Sep 18, 2025, 6:00 AM EDT - 16 days ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Sep 10, 2025, 6:00 AM EDT - 24 days ago

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

Aug 20, 2025, 9:25 AM EDT - 6 weeks ago

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Aug 19, 2025, 6:00 AM EDT - 6 weeks ago

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Aug 13, 2025, 6:00 AM EDT - 7 weeks ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Aug 11, 2025, 6:00 AM EDT - 7 weeks ago

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Apr 3, 2025, 8:00 AM EDT - 6 months ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Apr 2, 2025, 6:00 AM EDT - 6 months ago

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Mar 27, 2025, 6:00 AM EDT - 6 months ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Mar 17, 2025, 6:45 AM EDT - 7 months ago

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Feb 10, 2025, 6:00 AM EST - 8 months ago

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Jan 29, 2025, 6:00 AM EST - 8 months ago

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Jan 27, 2025, 6:00 AM EST - 8 months ago

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Jan 23, 2025, 6:00 AM EST - 9 months ago

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Jan 22, 2025, 6:00 AM EST - 9 months ago

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

Jan 17, 2025, 8:20 AM EST - 9 months ago

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Jan 14, 2025, 6:15 AM EST - 9 months ago

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Greenwich LifeSciences Partners with GIM in Italy

Nov 26, 2024, 6:00 AM EST - 11 months ago

Greenwich LifeSciences Partners with GIM in Italy

Greenwich LifeSciences Provides Update on Corporate Events

Nov 18, 2024, 6:00 AM EST - 11 months ago

Greenwich LifeSciences Provides Update on Corporate Events

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Aug 1, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100

Jun 26, 2024, 2:05 PM EDT - 1 year ago

Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Jun 26, 2024, 7:33 AM EDT - 1 year ago

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Greenwich LifeSciences Announces $2.5 Million Private Placement

Jun 14, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Announces $2.5 Million Private Placement

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Mar 13, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Mar 12, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Feb 27, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Feb 22, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Feb 14, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Nov 21, 2023, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Greenwich LifeSciences Provides Year End Update

Dec 29, 2022, 6:48 AM EST - 3 years ago

Greenwich LifeSciences Provides Year End Update

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Dec 1, 2022, 6:00 AM EST - 3 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Greenwich LifeSciences: Persevering CEO And Interesting Data

Sep 6, 2022, 5:40 PM EDT - 3 years ago

Greenwich LifeSciences: Persevering CEO And Interesting Data

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Aug 11, 2022, 10:30 AM EDT - 3 years ago

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Aug 3, 2022, 8:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Jul 28, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Here's Why Greenwich Lifesciences Shares Are Popping Off Today

Jul 12, 2022, 1:18 PM EDT - 3 years ago

Here's Why Greenwich Lifesciences Shares Are Popping Off Today

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Jul 12, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Jul 11, 2022, 4:15 PM EDT - 3 years ago

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Greenwich LifeSciences to Resume Stock Repurchase Program

May 23, 2022, 7:00 AM EDT - 3 years ago

Greenwich LifeSciences to Resume Stock Repurchase Program

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

May 23, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

Greenwich LifeSciences: A First Look

May 19, 2022, 11:12 AM EDT - 3 years ago

Greenwich LifeSciences: A First Look

Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

Apr 21, 2022, 8:55 AM EDT - 3 years ago

Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

Apr 20, 2022, 6:10 AM EDT - 3 years ago

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

Apr 19, 2022, 6:21 AM EDT - 3 years ago

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

Mar 3, 2022, 9:19 AM EST - 3 years ago

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

Feb 3, 2022, 6:00 AM EST - 3 years ago

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Feb 1, 2022, 6:00 AM EST - 3 years ago

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

Jan 24, 2022, 6:00 AM EST - 4 years ago

Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

Rolltide2020
Rolltide2020 Oct. 4 at 12:38 PM
$GLSI For what it’s worth:
0 · Reply
Alwaysdiversify
Alwaysdiversify Oct. 3 at 2:14 PM
$GLSI Of the 4 basic operations of arithmetic, the one I relish the most is multiplication. For example: My 20,275 shares of GLSI x $100 (my admittedly conservative estimate of a buyout price) = $2,027,500. And, 100% of that will be taxed as long-term capital gains.
4 · Reply
Gulfoil
Gulfoil Oct. 3 at 1:22 PM
$GLSI i dont know but hopefully no one fell victim to the head fake to go back below $10……this is going up. Where it deserves to trade.
2 · Reply
Rolltide2020
Rolltide2020 Oct. 3 at 9:07 AM
$GLSI So which European country are we adding today?
1 · Reply
doc123266
doc123266 Oct. 2 at 10:19 PM
$GLSI green day always nice.
0 · Reply
Edgehockey
Edgehockey Oct. 2 at 6:17 PM
$GLSI The only stock whose shorts are in a more precarious situation is VKTX. Hope you rats are short that name too. My QURE burnt many of you.
0 · Reply
Edgehockey
Edgehockey Oct. 2 at 6:15 PM
$GLSI Shorts- you are in for a world full of hurt. No sellers. You better smash the stock down and spend some more bullets. Spread some rumors on Seeking Alpha and shake out the fearful longs. If GLSI-100 has any performance close to P2, you will be covering at $100/ share.
1 · Reply
Rolltide2020
Rolltide2020 Oct. 2 at 5:29 PM
$GLSI With all this good news lately, we are due to go on a heater soon.
0 · Reply
Edgehockey
Edgehockey Oct. 2 at 2:49 PM
$GLSI Binary: longs downside is $8 bucks.....shorts, $80 bucks. LMFAO.
0 · Reply
Gulfoil
Gulfoil Oct. 2 at 12:09 PM
$GLSI pretty annoying you have to call in to buy
1 · Reply
Edgehockey
Edgehockey Oct. 2 at 10:30 AM
$GLSI Another country site announced. If there was any inkling that GLSI-100 sucked, why go through the time, trouble and expense of broadening the trial? Makes no sense and Snehal seems like a man of reason. As to the lack of his insider buying, my hunch: he cannot because he has surely been approached by BP and a potential deal is fairly in place. Too many clues that where there is smoke there is fire. Shorts...good luck. It's binary for those rats too.
2 · Reply
Alwaysdiversify
Alwaysdiversify Oct. 2 at 10:25 AM
$GLSI Add Belgium to the growing list of participating countries! https://investor.greenwichlifesciences.com/news-events/press-releases/detail/105/flamingo-01-clinical-trial-to-belgium
0 · Reply
Rolltide2020
Rolltide2020 Oct. 2 at 10:21 AM
$GLSI According to Chatgpt:
1 · Reply
Rolltide2020
Rolltide2020 Oct. 1 at 1:59 PM
$GLSI This sounds like a good thing to me. I hope shares are hard to come by. Just wait until 1.2 million shares need to be bought back.
4 · Reply
Gulfoil
Gulfoil Oct. 1 at 1:43 PM
$GLSI XBI closing in on 2 x year highs….good sign as far as money coming into biotech….now just need GLSI to go make 2yr highs
0 · Reply
msgbrdinfo
msgbrdinfo Oct. 1 at 12:40 PM
$GLSI We have officially made it to 2025 Q4 with no interim which is a good thing. The new trial locations recently in Ireland and Portugal don't necessarily confirm things are going great with Flamingo-01 but I would argue that they confirm things are not going bad.
1 · Reply
suspendFlow
suspendFlow Sep. 30 at 8:06 PM
$GLSI ok so what do we know: 1. GLSI to present in SABCS 2025, late breaking abstract deadline is today (can we know if they entered due to LBA?) 2. Sites keep on being added, even today, years into phase3 3. Fast track granted 4. No insiders bought for a long while 5. No offering (ATM being tapped as stock price is rekt?) 6. No serious adverse effects reported yet 7. Phase3 started AUG 22 In Q1 2025 company reported 150 screened per quarter. So a modest (IMO) number of treated patients could be 50 2022-2023 175 2024 175 2025 = 400 If follow up is 1.5 years And we take typical reccurence rate (~4%) we get 400 * 1.5 * 0.04 = 24 events if treatment is 0% effective Or 12 events if it is 100% effective But peak immunity happens at 6 months So even 100% effective would still get ~4 events in treatment arm That would be 8 placebo, 4 treatment We didn't hit 14 events yet Absolutely no buying pressure Thoughts? ;d
4 · Reply
Lukeing_At_Stocks
Lukeing_At_Stocks Sep. 30 at 7:56 PM
$GLSI Kind of annoying you have to call brokers to buy shares now
2 · Reply
msgbrdinfo
msgbrdinfo Sep. 30 at 7:32 PM
$GLSI I couldn't imagine GLSI not being at SABCS.
0 · Reply
Hbhatwala
Hbhatwala Sep. 30 at 6:20 PM
$GLSI Booth no 947 Price 52 week high will be $947
0 · Reply
Rolltide2020
Rolltide2020 Sep. 30 at 6:04 PM
$GLSI Not sure if anyone has already posted, but it looks like we have a booth and a meeting room again at SABCS. https://sabcs2025.mapyourshow.com/8_0/exhview/index.cfm?orsearchtype0=exhibitor&orsearchvalue0=318&orsearchdisplay0=Exhibitor&orsearchvaluedisplay0=Greenwich%20LifeSciences%2C%20Inc.&selectedBooth=MR-603
3 · Reply
Rolltide2020
Rolltide2020 Sep. 30 at 5:45 PM
$GLSI Oh look, it's Mr. No Position BB. I'm guessing Fake MBA is right around the corner.
2 · Reply